Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology
+$0.03 today
- Market cap
- $103.50M
- Beta
- 0.42
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.19
Volume 1.28M
Average 0.21M
TLSA Total Liabilities
Everything the company owes to creditors and other parties.
Tiziana Life Sciences LtdNASDAQ: TLSA
Total Liabilities · Q4 FY2025 · quarter ended Dec 2025
Total liabilities rises 55.7% from a year ago
Total liabilities stood at $11.44M at the end of Q4 FY2025, up 55.7% from a year earlier. Over 3 fiscal years it compounded at +18.3% a year.
Context
- Total liabilities amounted to 99.5% of total assets at the end of Q4 FY2025, up 34.4 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +55.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 11.44M USD
- Year-over-year change
- +55.7%
- 4-year CAGR
- +11.0%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.44M | +55.7% |
| FY2024 | 2024-12-31 | 7.35M | +10.5% |
| FY2023 | 2023-12-31 | 6.65M | -3.7% |
| FY2022 | 2022-12-31 | 6.91M | -8.5% |
| FY2021 | 2021-12-31 | 7.55M | — |
Total Liabilities vs competitors
How TLSA compares with its peers on the latest reported figures
- TLSA's Dec 2025 total liabilities of $11.44M is the 5th highest of the 9 companies compared; the peer median is $11.25M.
- Its year-over-year change of +55.7% is the highest of 9, against a peer median of -12.3%.
- Total liabilities amounts to 99.5% of total assets for TLSA, versus a peer median of 23.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $196.68M | +35.2% | +10.9% | 90.3% | |
| Mar 2026 | $70.39M | -20.6% | -15.2% | 27.8% | |
| Mar 2026 | $37.43M | -57.3% | +5.7% | 18.5% | |
| Mar 2026 | $11.45M | +11.2% | +84.9% | 12.0% | |
| Dec 2025 | $11.44M | +55.7% | +18.3% | 99.5% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $11.06M | -9.9% | -17.5% | 8.7% |
| Sep 2025 | $8.06M | -19.8% | +89.6% | 173.5% | |
| Mar 2026 | $4.3M | -14.6% | -25.6% | 8.1% | |
EXOZeXoZymes, Inc. | Mar 2026 | $2.49M | -5.8% | +25.2% | 62.0% |
| Peer median (excluding TLSA) | $11.25M | -12.3% | +8.3% | 23.1% | |
Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 42.19M | 18.12M | 1.18M | 3.72M | 4.01M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 5.27M | 5.86M | 6.05M | 3.69M | 4.26M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 48.68M | 24.28M | 7.34M | 7.51M | 8.55M |
| Property, Plant & Equipment (Net) | 17K | 389K | 293K | 187K | 499K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 130K | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 1.81M | 4.55M | 3.59M | 2.44M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 147K | 2.2M | 4.85M | 3.78M | 2.94M |
| Total Assets | 48.83M | 26.48M | 12.18M | 11.28M | 11.5M |
| Account Payables | 4.41M | 4.96M | 4.14M | 5.58M | 7.17M |
| Short-term Debt | 1.36M | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 530K |
| Other Current Liabilities | (1.35M) | 9K | 14K | 12K | (3K) |
| Total Current Liabilities | 7.55M | 6.66M | 6.54M | 7.35M | 11.21M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 243K | 109K | 0 | 234K |
| Total Liabilities | 7.55M | 6.91M | 6.65M | 7.35M | 11.44M |
| Common Stock | 102K | 102K | 103K | 111K | 121K |
| Retained Earnings | (108.06M) | (116.26M) | (133.68M) | (144.83M) | (44.41M) |
| Accumulated OCI | 119.15M | 115.57M | 117.06M | 116.99M | 9.68M |
| Other Stockholders Equity | 14.49M | 5.89M | 7.13M | 8.56M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 41.28M | 19.57M | 5.54M | 3.94M | 52K |
| Total Debt | 1.36M | 365K | 247K | 106K | 456K |
| Net Debt | (40.83M) | (17.76M) | (936K) | (3.62M) | (3.55M) |
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.